TABLE 4.
Outcome-associated characteristics of 37 patients
| Variable | Outcome |
Univariate analysis |
Multivariable analysis |
|||
|---|---|---|---|---|---|---|
| Survival | Death | OR (95% CI) | P value | aORa (95% CI) | P value | |
| Median age (yr) | 33 (28–36) | 35 (31–38) | 1.0 (0.9–1.2) | 0.59 | ||
| Sex | ||||||
| No. (%) of males | 15/23 (65.2) | 5/14 (35.7) | Reference | Reference | ||
| No. (%) of females | 8/23 (34.8) | 9/14 (64.3) | 3.4 (0.8–13.6) | 0.08 | 2.14 (0.44–10.36) | 0.34 |
| Province | ||||||
| Gauteng | 1/22 (4.6) | 4/12 (33.3) | Reference | |||
| Western Cape | 19/22 (86.4) | 8/12 (66.7) | 0.11 (0.01–1.1) | 0.06 | ||
| Eastern Cape* | ||||||
| Free State | 2/22 (9.1) | 0/12 (0) | ||||
| Median no. of CD4 cells/μl (IQR) | 13 (9–32) | 14 (6–27) | 1.0 (0.98–1.04) | 0.50 | ||
| ART history | ||||||
| No. naive/total (%) | 6/21 (28.6) | 3/10 (30) | Reference | |||
| No. experienced/total (%) | 15/21 (71.4) | 7/10 (70) | 0.93 (0.17–4.87) | 0.94 | ||
| Any antifungal treatment | ||||||
| No. without/total (%) | 0/22 (0) | 6/11 (54.6) | Reference | |||
| No. with/total (%) | 22/22 (100) | 5/11 (45.5) | 1 | |||
| Specimen type | ||||||
| No. of skin biopsy samples/total (%) | 15/23 (65.2) | 2/14 (14.3) | Reference | Reference | ||
| No. of blood cultures/total (%) | 6/23 (26.1) | 8/14 (57.1) | 10 (1.62–61.47) | 0.01 | 8.57 (1.35–54.33) | 0.02 |
| No. of bone marrow aspirates/total (%) | 2/23 (8.7) | 4/14 (28.6) | 15 (1.58–142.18) | 0.02 | 12.1 (1.21–120.13) | 0.03 |
| Antifungal MIC50 | ||||||
| Amphotericin Bb | 0.06 | 0.06 | 0.16 (0.001–20.82) | 0.47 | ||
| Posaconazolec | 0.008 | 0.008 | 1.91 (0.10–34.82) | 0.66 | ||
| Itraconazolec | 0.008 | 0.008 | 0.26 (0.0004–140.69) | 0.67 | ||
| Voriconazolec | 0.008 | 0.008 | 72.3 (9.89–5.30) | 0.87 | ||
| Fluconazolec | 0.12 | 0.20 | 0.75 (0.29–1.92) | 0.54 | ||
a
aOR, adjusted OR.
b
Determined by Etest, yeast phase.
c
Determined by BMD, mold phase.